1. Home
  2. SBI vs MGNX Comparison

SBI vs MGNX Comparison

Compare SBI & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SBI
  • MGNX
  • Stock Information
  • Founded
  • SBI 1992
  • MGNX 2000
  • Country
  • SBI United States
  • MGNX United States
  • Employees
  • SBI N/A
  • MGNX N/A
  • Industry
  • SBI Finance/Investors Services
  • MGNX Biotechnology: Pharmaceutical Preparations
  • Sector
  • SBI Finance
  • MGNX Health Care
  • Exchange
  • SBI Nasdaq
  • MGNX Nasdaq
  • Market Cap
  • SBI 111.4M
  • MGNX 99.7M
  • IPO Year
  • SBI N/A
  • MGNX 2013
  • Fundamental
  • Price
  • SBI $7.96
  • MGNX $1.81
  • Analyst Decision
  • SBI
  • MGNX Hold
  • Analyst Count
  • SBI 0
  • MGNX 6
  • Target Price
  • SBI N/A
  • MGNX $3.20
  • AVG Volume (30 Days)
  • SBI 39.5K
  • MGNX 630.9K
  • Earning Date
  • SBI 01-01-0001
  • MGNX 11-04-2025
  • Dividend Yield
  • SBI 4.52%
  • MGNX N/A
  • EPS Growth
  • SBI N/A
  • MGNX N/A
  • EPS
  • SBI N/A
  • MGNX N/A
  • Revenue
  • SBI N/A
  • MGNX $165,495,000.00
  • Revenue This Year
  • SBI N/A
  • MGNX N/A
  • Revenue Next Year
  • SBI N/A
  • MGNX N/A
  • P/E Ratio
  • SBI N/A
  • MGNX N/A
  • Revenue Growth
  • SBI N/A
  • MGNX 303.47
  • 52 Week Low
  • SBI $6.96
  • MGNX $0.99
  • 52 Week High
  • SBI $8.00
  • MGNX $5.10
  • Technical
  • Relative Strength Index (RSI)
  • SBI 64.22
  • MGNX 51.87
  • Support Level
  • SBI $7.86
  • MGNX $1.69
  • Resistance Level
  • SBI $7.99
  • MGNX $1.83
  • Average True Range (ATR)
  • SBI 0.06
  • MGNX 0.10
  • MACD
  • SBI -0.00
  • MGNX 0.00
  • Stochastic Oscillator
  • SBI 86.17
  • MGNX 56.00

About SBI Western Asset Intermediate Muni Fund Inc

Western Asset Intermediate Muni Fd Inc is a diversified closed-end management investment company. The fund's objective is to provide a high level of current income exempt from Federal income taxes. Under normal market conditions, the Fund will invest at least 80% of its total assets in municipal obligations. In addition, under normal market conditions, the Fund will invest at least 80% of its total assets in debt securities that are, at the time of investment, rated investment grade by a nationally recognized statistical rating organization or, if unrated, of equivalent quality as determined by the investment manager. The Fund also maintains a dollar-weighted average effective maturity of between three and ten years.

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Share on Social Networks: